Serological markers of hepatitis B virus and cytomegalovirus infections in Norwegians with coagulation factor defects.
The prevalence of serological markers for present and past hepatitis B virus (HBV) infection and antibodies against cytomegalovirus (CMV) among Norwegians with coagulation factor defects was examined in serum samples collected before virus-inactivated coagulation concentrates came into use. Sera collected in 1985/86 from 324 of 377 (86%) registered persons with such defects were available. Three persons were chronic carriers of HBsAg. The prevalence of HBV antibodies was 28% compared with about 5% in the general population. The highest prevalence rate was found among patients with severe haemophilia A (44%) and in patients with haemophilia B (39%). The prevalence of anti-CMV antibodies was 75% which is similar to that found in the general Norwegian population.
Rollag
H
H
Institute of Bacteriology, Rikshospitalet, Oslo, Norway.
Evensen
S A
SA
Frøland
S S
SS
Glomstein
A
A
D000914:Antibodies, Viral / Q000032:analysis; D001778:Blood Coagulation Disorders / Q000453:epidemiology; D003587:Cytomegalovirus / Q000276:immunology; D003586:Cytomegalovirus Infections / Q000453:epidemiology* / Q000635:transmission; D006467:Hemophilia A / Q000276:immunology; D006509:Hepatitis B / Q000453:epidemiology* / Q000635:transmission; D006510:Hepatitis B Antibodies / Q000032:analysis; D006801:Humans; D009664:Norway; D015995:Prevalence
D000914:Antibodies, Viral; D006510:Hepatitis B Antibodies